Safety and efficacy of immunotherapy rechallenge following checkpoint inhibitor-related pneumonitis in advanced lung cancer patients: a retrospective multi-center cohort study

BACKGROUND: Checkpoint inhibitor-related pneumonitis (CIP) induced by immune checkpoint inhibitors (ICIs) is one of the most fatal immune-related adverse events (irAE). However, only limited data are available on rechallenge with ICIs after CIP. We evaluated the efficacy and safety of rechallenge af...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Xinqing, Deng, Haiyi, Chu, Tianqing, Chen, Likun, Yang, Yilin, Qiu, Guihuan, Xie, Xiaohong, Qin, Yinyin, Liu, Ming, Xie, Zhanhong, Ouyang, Ming, Li, Shiyue, Song, Yong, Petrella, Francesco, Jakopovic, Marko, Tsoukalas, Nikolaos, Solli, Piergiorgio, Goto, Taichiro, Saito, Yuichi, Zhou, Chengzhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742619/
https://www.ncbi.nlm.nih.gov/pubmed/36519018
http://dx.doi.org/10.21037/tlcr-22-732

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742619/
https://www.ncbi.nlm.nih.gov/pubmed/36519018
http://dx.doi.org/10.21037/tlcr-22-732

Ejemplares similares